Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.
Your search for major depressive disorder returned 61 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.
Investigators sought to characterize psychotropic drugs used to treat patients with bipolar disorder and assess changes in medication treatments in acute and maintenance episodes, and overall adherence.
Researchers seek to evaluate whether trauma-focused therapy adjunctive to treatment as usual (TAU) leads to a greater reduction of depressive symptoms posttreatment vs TAU exclusively in patients with major depressive disorder with childhood trauma.
The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.
Investigators sought to assess associations for US Army soldiers bullied by fellow soldiers with mental health outcomes.
Investigators searched publication databases for studies that evaluated the association between childhood maltreatment and mental health outcomes.
Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.
The REAL-ESK study was an observational, retrospective, multicenter study conducted in Italy.
Children and adolescents were evaluated for receipt of antipsychotics between 2000 and 2019 in England.
Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.
Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
Investigators from the Veteran’s Affairs Center for Innovation to Implementation and Stanford University searched publication databases through June 2022 for observational studies about methamphetamine-associated heart failure.
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Researchers examined correlations between suicidal ideation and suicide attempt history in patients with treatment-resistant depression following ketamine infusion.
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses